



Systematic Review Analgesic Efficacy and Safety of Tapentadol Immediate Release in Bunionectomy: A Meta-Analysis

Lorenzo Franco-de la Torre ^{1,†}, Eduardo Gómez-Sánchez ^{2,†}, Othoniel Hugo Aragon-Martinez ³, Adriana Hernández-Gómez ^{1,4}, Diana Laura Franco-González ¹, Juan Manuel Guzmán-Flores ⁴, Angel Josabad Alonso-Castro ⁵, Vinicio Granados-Soto ⁶ and Mario Alberto Isiordia-Espinoza ^{1,*}

- ¹ Instituto de Investigación en Ciencias Médicas, Cuerpo Académico Terapéutica y Biología Molecular (UDG-CA-973), Departamento de Clínicas, División de Ciencias Biomédicas, Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos 47620, Mexico; lorenzo.franco@academicos.udg.mx (L.F.-d.I.T.); adriana.hgomez@academicos.udg.mx (A.H.-G.); diana.franco5288@alumnos.udg.mx (D.L.F.-G.)
- ² División de Disciplinas Clínicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico; eduardo.gsanchez@academicos.udg.mx
- ³ Laboratorio de Productos Naturales, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí 78210, Mexico; hugo.aragon@uaslp.mx
- ⁴ Departamento de Ciencias de la Salud, División de Ciencias Biomédicas, Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos 47620, Mexico; juan.guzman@cualtos.udg.mx
- ⁵ Departamento de Farmacia, División de Ciencias Naturales y Exactas, Universidad de Guanajuato, Guanajuato 36040, Mexico; angeljosabad@hotmail.com
- ⁶ Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Cinvestav, South Campus, Mexico City 14330, Mexico; vinicio_granadossoto@hotmail.com
- Correspondence: mario.isiordia162@yahoo.com; Tel.: +52-(378)-122-09-92
- [†] These authors contributed equally and both could be considered the first authors.

Abstract: The aim of this systematic review and meta-analysis was to evaluate the analgesic effect of different doses of tapentadol immediate release (IR) and its adverse effects after a bunionectomy. Pubmed, Cochrane, Lilacs, Medline, and Imbiomed were used to identify abstracts of scientific publications related to the keywords of this systematic review (PROSPERO ID CRD42023437295). Moreover, the risk of bias in all included articles was assessed using the Cochrane Collaboration risk of bias tool. Data on the sum of pain intensity, total pain relief, global assessment, and adverse effects were extracted. The statistical method of inverse variance with means difference was used to evaluate the numerical data and the Mantel-Haenszel and Odd Ratio test to analyze the dichotomous data. In addition, the number needed to treat, the number needed to harm, and the 95% confidence intervals were calculated. A qualitative evaluation (n = 2381) was carried out according to the conclusions of the authors. Tapentadol (n = 1772) was more effective in relieving postoperative pain than the placebo (n = 609) after a bunionectomy. In addition, the analgesic efficacy of IR tapentadol (n = 1323) versus the placebo (n = 390) was evaluated in a total of 1713 patients using a global evaluation of the treatments. All three doses of IR tapentadol showed better results compared to the placebo after a bunionectomy. Finally, the adverse effects have a direct relationship with the dose, and the greatest number of adverse effects are most observed with tapentadol IR 100 mg (n = 2381). It is concluded that tapentadol IR (100 mg) leads to the best satisfaction score in this meta-analysis.

Keywords: tapentadol; hallux valgus surgery; bunionectomy; pain control; adverse effects

1. Introduction

Postoperative pain after a bunionectomy occurs during the first 24 h post-surgery, and the patient may experience bouts of pain for several days [1,2]. This surgical procedure is considered a characterized clinical model for the evaluation of postoperative pain [1–3].



Citation: Franco-de la Torre, L.; Gómez-Sánchez, E.; Aragon-Martinez, O.H.; Hernández-Gómez, A.; Franco-González, D.L.; Guzmán-Flores, J.M.; Alonso-Castro, A.J.; Granados-Soto, V.; Isiordia-Espinoza, M.A. Analgesic Efficacy and Safety of Tapentadol Immediate Release in Bunionectomy: A Meta-Analysis. *Pharmaceuticals* **2023**, *16*, 1287. https://doi.org/ 10.3390/ph16091287

Academic Editor: Marco Fiore

Received: 9 August 2023 Revised: 4 September 2023 Accepted: 9 September 2023 Published: 12 September 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Therefore, a bunionectomy is a very important clinical tool for developing new analgesics or evaluating the clinical efficacy and safety profile of currently marketed drugs [1–4].

The most common postoperative analgesic treatment after bunion surgery mainly includes the use of non-steroidal anti-inflammatory agents (NSAIDs) [1] and opioid analgesic drugs [2]. In addition, various analgesic regimens can be used (e.g., pre-preventive analgesia, a combination of drugs to employ multimodal analgesia, and local analgesia) [5]. An analgesic monotherapy approach is common, and one of the most widely used opioid drugs in published clinical trials has been tapentadol immediate release (IR) [6–12]. However, tapentadol is a relatively new drug and limited scientific evidence of its analgesic efficacy in a bunionectomy can be found in a few individual clinical trials [6–12].

Based on the results of these trials, tapentadol has clinical efficacy for pain control similar to oxycodone [8,10] or morphine [11]. However, the most effective dose of tapentadol IR based on its clinical efficacy and adverse effects in a bunionectomy has not been defined. For this reason, the purpose of this systematic review and meta-analysis was to assess the analgesic effect of different doses of tapentadol IR and its adverse effects after a bunionectomy.

2. Material and Methods

2.1. Information Search

Pubmed, Cochrane, Lilacs, Medline, and Imbiomed were used to identify abstracts of scientific publications related to the keywords of this systematic review. The following search terms were used for the Pubmed, Cochrane, Lilacs, and Medline databases: "tapentadol" AND "bunionectomy"; "tapentadol" AND "hallux valgus surgery"; "tapentadol" AND "orthopedic surgery"; "µ-opioid receptor agonist" AND "bunionectomy"; "μ-opioid receptor agonist" AND "hallux valgus surgery"; "μ-opioid receptor agonist" AND "orthopedic surgery"; "noradrenaline reuptake inhibitor" AND "bunionectomy"; "noradrenaline reuptake inhibitor" AND "hallux valgus surgery"; "noradrenaline reuptake inhibitor" AND "orthopedic surgery"; "opioid" AND "bunionectomy"; "opioid" AND "hallux valgus surgery"; and "opioid" AND "orthopedic surgery". On the other hand, a single-term search was used for the Imbiomed database. Filters for study type/design and language ("English" and "Spanish") were used. This activity was performed by two independent researchers. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO ID CRD42023437295) of the National Institute of Health and Care Research at the University of York. Articles published up to 30 May 2023, were eligible.

2.2. Population, Interventions, Control, and Outcome Strategy (Inclusion Criteria)

Population: Patients undergoing a bunionectomy.

Interventions: Administration of tapentadol IR.

Control: Placebo.

Outcome: Sum of pain intensity (SPID), total pain relief (TOTPAR), global evaluation, and adverse effects.

2.3. Exclusion Criteria

Clinical studies reporting a loss to follow-up of more than 20%. High risk of bias according to the Cochrane Collaboration risk of bias tool.

2.4. Assessment of Bias

Quality assessment of each clinical assay was performed with the Cochrane Collaboration risk of bias tool [13–15]. The studies without a high risk of bias were deliberated like of high quality. Two independent researchers made a full evaluation of each report and discussed their differences to obtain a consensus [13–17].

2.5. Data Extraction

Extracted data were as follows: author, design study, treatment groups, size sample (n), dose, SPID, TOTPAR, adverse effects on the gastrointestinal tract (nausea, vomiting, constipation), and adverse effects on the nervous system (dizziness, somnolence, and headache).

2.6. Statistical Analysis

Inverse variance statistical methods with means difference were used to assess the numerical data. The Mantel–Haenszel test and the Odd Ratio (OR) were utilized to analyze dichotomous data. In order to follow a conservative statistical method, all meta-analyzes were made with a random effect model employing the Review Manager Software 5.3 for Windows. In addition, inconsistency or heterogeneity was assessed using the I² value in each meta-analysis. Low heterogeneity was considered when the I² value was between 0% and 30%, moderate heterogeneity when the I² value was between 31% and 60%, and high heterogeneity when the I² value was between 61% and 100%. A *p*-value overall test <0.05 and an OR (>1 and within the 95% confidence interval (CI)) deliberated a statistical difference [14,18–20].

The number needed to treat (NNT), the number needed to harm (NNH), and the 95% CI were calculated for the global evaluation and adverse effects using the Risk Reduction Calculator from the University of Illinois at Chicago [21].

3. Results

3.1. Information Search and Bias

A total of 2860 abstract publications were identified in the databases used, of which only 7 abstracts were considered for full-text evaluation. These articles were then fully assessed using the PICO criteria and the Cochrane Bias Assessment Tool. These same seven articles were considered for the qualitative evaluation, and six were considered for the statistical analysis (Figures 1 and 2) [6–12].




Figure 1. Study flow diagram.




Figure 2. Assessment of risk of bias [6–12]. + = Low risk of bias? = Unclear risk of bias.

3.2. Qualitative Assessment

A total of seven studies were included in the qualitative evaluation (n = 2381). According to the authors' conclusions, tapentadol (n = 1772) was more effective in relieving postoperative pain than the placebo (n = 609) after a bunionectomy (Table 1).

3.3. Quantitative Evaluation

The pooled analysis of the SPID endpoint comparing tapentadol IR versus the placebo was performed using three clinical trials. Tapentadol IR 50 mg (n = 261) and tapentadol IR 75 mg (n = 256) were more effective for postoperative pain control than the placebo (n = 254) at 24, 48, and 72 postoperative hours (Figure 3) [6,7,9]. In addition, the uncertainty, assessed through the heterogeneity of the data, showed mainly low heterogeneity; however, two time points showed moderate heterogeneity, so we decided to use a random effects model (Figure 3) [6,7,9].

ID Study and Study Design	Treatments (<i>n</i>)	Details of Patients, Surgical Procedure, and Evaluation	Authors' Conclusion
Chen et al., 2015 [6]. Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial.	Group A: Tapentadol IR 50 mg (<i>n</i> = 21). Group B: Tapentadol IR 75 mg (<i>n</i> = 19). Group C: Placebo (<i>n</i> = 20). The treatments were given orally every 4–6 h over a 72 h period.	 Healthy or medically stable patients aged 20 to 80 years needing a first metatarsal bunionectomy were included. The bunionectomy was made using standardized surgical procedures. The continuous popliteal sciatic block was used. The taking of drugs that interfered with the perception of postoperative pain, such as opioid analgesics or other analgesic or sedative medications, was not allowed during the treatment phase. Subjects who took a different drug than the study drug were discontinued from the clinical trial because of a lack of analgesic efficacy. Pain intensity, pain relief, patient global assessment, SPID, TOTPAR, pain intensity difference (SPRID), and adverse effects were evaluated. 	Tapentadol relieved moderate to severe acute pain and had an acceptable safety profile compared to the placebo.
Daniels et al., 2009 [7]. Phase 3, randomized, double-blind, placebo-and-active-controlled, parallel-group, multicenter clinical assay.	Group A: Tapentadol IR 50 mg ($n = 119$). Group B: Tapentadol IR 75 mg ($n = 120$). Group C: Tapentadol IR 100 mg ($n = 118$). Group D: Oxycodone HCl IR 15 mg ($n = 125$). Group E: Placebo ($n = 120$). The treatments were given orally every 4–6 h over a 72 h period.	ASA-1-to-3 patients aged 18 to 80 years who had a pain score ≥ 4 after the bunionectomy were eligible. The continuous popliteal sciatic block was used. Rescue medication with acetaminophen, ketorolac, and/or hydrocodone/acetaminophen combination was allowed. SPID, TOTPAR, patient global evaluation, and adverse effects were evaluated.	Tapentadol had better analgesic efficacy and lower adverse effects when compared to the placebo. Tapentadol 100 mg had similar analgesic activity to 15 mg of oxycodone.

Table 1. Characteristics of the included studies.

Details of Patients, Surgical Procedure, and ID Study and Study Design Treatments (n) Authors' Conclusion Evaluation Daniels et al., 2009 [8]. Group A: Tapentadol IR 50 mg ASA-1 and ASA-2 patients aged 18 to 80 years Tapentadol relieved moderate to severe acute Phase 3, randomized, double-blind, who had a pain score > 4 after the bunionectomy (n = 275).pain and had an acceptable safety profile Group B: Tapentadol IR 75 mg placebo-and-active-controlled, were eligible. compared to the placebo. Furthermore, both parallel-group, multicenter study. (n = 278).The continuous popliteal sciatic block was used. doses of tapentadol were not inferior Patients were allowed up to 2 g of acetaminophen Group C: Oxycodone HCl IR 10 mg (n = 278). to oxycodone. Group D: Placebo (n = 69). after receipt of the first dose of study medication. The treatments were given orally every 4–6 h SPID, TOTPAR, patient global evaluation, and adverse effects were evaluated. over a 72 h period. Lee et al., 2014 [9]. Group A: Tapentadol IR 50 mg Healthy or medically stable patients aged 20 to Tapentadol relieved the acute pain when 80 years needing a first metatarsal bunionectomy Phase 3, randomized, double-blind, (n = 121).compared to the placebo. placebo-controlled, parallel-group, Group B: Tapentadol IR 75 mg were included. multicenter clinical trial. (n = 117).The 0.5% mepivacaine continuous popliteal sciatic Group C: Placebo (n = 114). block was used. Acetaminophen at a dose of 650 mg taken orally The treatments were given orally every 4–6 h over a 72 h period. (PO) and/or ketorolac at a dose of 30 mg IV every 4–6 h, or alternatively fentanyl at a dose of 100 µg IV were used as supplemental analgesia until the start of the qualifying period. SPID, TOTPAR, SPRID, global evaluation, and adverse effects were evaluated. Stegmann et al., 2008 [10]. Group A: Tapentadol IR 50 mg Healthy or medically stable patients aged 18 to Both tapentadol and oxycodone were effective Phase II, randomized, double-blind, (n = 67).65 years needing a first metatarsal bunionectomy in postoperative pain control. placebo-controlled, parallel-group, Group B: Tapentadol IR 100 mg were included. multiple-dose clinical assay. (n = 68).The 0.5% mepivacaine sciatic block was used. Group C: Oxycodone HCl IR 10 mg (n = 67). The use of analgesics, sedatives, and narcotic Group D: Placebo (n = 67). drugs 12 h before surgery was not allowed. The treatments were given orally every 4–6 h Ibuprofen, ketorolac, and the over a 72 h period. hydrocodone-acetaminophen combination as rescue medication were used. SPID, TOTPAR, analgesic consumption, global evaluation, and adverse effects were evaluated.

Table 1. Cont.

ID Study and Study Design	Treatments (n)	Details of Patients, Surgical Procedure, and Evaluation	Authors' Conclusion
Viscusi et al., 2019 [11]. Phase 3, randomized, double-blind, placebo-and-active-controlled, parallel-group, multicenter trial.	Group A: Tapentadol IR 75 mg ($n = 96$). Group B: Morphine 30 mg ($n = 96$). Group C: Placebo ($n = 99$). The treatments were given orally every 4–6 h over a 72 h period.	Patients aged 18 to 65 years needing a first metatarsal bunionectomy were included. The 0.5% mepivacaine continuous popliteal sciatic block was used. Paracetamol–hydrocodone combination rescue medication was used. SPID, the first intake of the investigational medicinal product, global evaluation, and adverse effects were evaluated.	Tapentadol was effective in postoperative pain control and was well-tolerated.
Xu et al., 2012 [12]. Randomized, double-blind, placebo-and-active-controlled, parallel-group, clinical trial.	Group A: Tapentadol IR 50 mg ($n = 118$). Group B: Tapentadol IR 75 mg ($n = 119$). Group C: Tapentadol IR 100 mg ($n = 116$). Group D: Oxycodone HCl IR 15 mg ($n = 123$). Group E: Placebo ($n = 120$). The treatments were given orally every 4–6 h over a 72 h period.	Healthy patients with moderate to severe pain following the bunionectomy. Data for regional anesthesia and rescue medication were not included. The adverse effects—nausea, vomiting, and constipation—were evaluated.	A decrease in the adverse effects of tapentadol compared to oxycodone was observed.

Table 1. Cont.

Oder de la Oriela de la Constantina		pentadol			lacebo			Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean			Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.1.1 Tapentadol 50 m	ng versus	placebo	at 24	postop	erative h	ours			
Chen et al., 2015	67.5	40.9	21	16.7	69.4	20	6.6%	50.80 [15.71, 85.89]	
Daniels et al., 2009a	46.6	53.39	119	5.2	52.33	120	44.6%	41.40 [28.00, 54.80]	
Lee et al., 2014 Subtotal (95% Cl)	48.1	47.92	121 261	17.7	51.88	114 254	48.8% 100.0%	30.40 [17.61, 43.19] 36.65 [27.62, 45.68]	•
Heterogeneity: Tau² = I				P = 0.36	i); I² = 1 %				
Test for overall effect: 2	Z = 7.95 (P ≺ 0.000	001)						
1.1.2 Tapentadol 50 m	ng versus	placebo	at 48	postop	erative h	ours			
Daniels et al., 2009a	119.1	125.86	119	24.5	120.93	120	48.0%	94.60 [63.30, 125.90]	-
Lee et al., 2014	131.7	107.19	121	65.3	121.04	114	52.0%	66.40 [37.10, 95.70]	
Subtotal (95% CI)			240			234	100.0%	79.94 [52.33, 107.56]	•
Heterogeneity: Tau² = * Test for overall effect: 2				1 (P = 0	.20); I² = 4	40%			
I.1.3 Tapentadol 50 m	ng versus	placebo	at 72	postop	erative h	ours			
Chen et al., 2015	281.3	129.5	21	91.6	252.9	20	9.6%	189.70 [65.80, 313.60]	· · · · · · · · · · · · · · · · · · ·
Daniels et al., 2009a		207.57	119		201.87	120	42.4%		
Lee et al., 2014	234.5	170.84	121	127.9	198.61	114	48.0%	106.60 [59.10, 154.10]	
Subtotal (95% CI)			261			254	100.0%	133.93 [94.17, 173.69]	•
Heterogeneity: Tau² = : Test for overall effect: 2				2 (P = 0	.28); I² = :	20%			
1.1.4 Tapentadol 75 m	ng versus	placebo	at 24	postop	erative h	ours			
Chen et al., 2015	82	57.7	19	7.6	32.2	20	17.7%	74.40 [44.87, 103.93]	-
Daniels et al., 2009a	60.5	53.94	120	5.2	52.33	120	42.0%	55.30 [41.85, 68.75]	
Lee et al., 2014	60.1	58.56	117	17.7	51.88	114	40.2%	42.40 [28.14, 56.66]	
Subtotal (95% CI)			256				100.0%	53.49 [38.95, 68.04]	•
Heterogeneity: Tau² = : Test for overall effect: 2				(P = 0.1	2); I ² = 5:	2%			
1.1.5 Tapentadol 75 m	ng versus	placebo	at 48	postop	erative h	ours			
Daniels et al., 2009a	10000	118.93	120	1000	120.93	120	51.6%	114.60 [84.25, 144.95]	
Lee et al., 2014		124.03	117	65.3	121.04	114	48.4%	89.20 [57.60, 120.80]	
Subtotal (95% CI)			237			234	100.0%	102.30 [77.42, 127.18]	•
Heterogeneity: Tau² = ` Test for overall effect: 2				(P = 0.2	26); I² = 23	3%			
1.1.6 Tapentadol 75 m	ng versus	placebo	at 72	postop	erative h	ours			
Chen et al., 2015	316.1	206.8	19	91.6	252.9	20	5.6%	224.50 [79.82, 369.18]	
Daniels et al., 2009a	230.5	189.36	120	55.7	201.87	120	48.1%	174.80 [125.28, 224.32]	
Lee et al., 2014	264.1	192.7		127.9	198.61	114	46.3%	136.20 [85.72, 186.68]	
Subtotal (95% CI)			256				100.0%	159.74 [125.40, 194.08]	•
Heterogeneity: Tau² = 1 Test for overall effect: 2				P = 0.38	l); I² = 0%				
									-200 -100 Ó 100 200 Placebo Tapentadol

Figure 3. Pooled data analysis of SPID [6,7,9].

The TOTPAR of tapentadol IR and the placebo were evaluated using data from four studies. The results show that the three doses of tapentadol IR—50 mg (n = 328), 75 mg (n = 256), and 100 mg (n = 186)—presented better analgesic efficacy than the placebo (n = 321, n = 254, and n = 187, respectively) at 12, 24, 48, and 72 postoperative hours (Figure 4) [6,7,9,10]. The evaluation of the data showed that the clinical indicator of analgesia TOTPAR mainly presented a high heterogeneity. For this reason, the data analysis was performed with a conservative approach using a random effects model (Figure 4) [6,7,9,10].

Study or Subgroup	Taj Mean	pentadol SD	Total N	Place Mean		al Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl
.2.1 Tapentadol 50 mg						-	re, nandom, 95% Cl	Nandom, 55% CI
Chen et al., 2015	22.5	10.3	21			20 6.0%	9.50 [2.87, 16.13]	
Daniels et al., 2009a	20.1	10.57	119	13.7 11.	74 12	20 32.8%	6.40 [3.57, 9.23]	-
_ee et al., 2014 Subtotal (95% CI)	15	8.94	121 261	7.8 7.	21 11	14 61.3% 54 100.0%	7.20 [5.13, 9.27] 7.08 [5.45, 8.70]	•
Heterogeneity: Tau² = 0. Test for overall effect: Z				= 0.69); l²	= 0%			
I.2.2 Tapentadol 50 mg								
Chen et al., 2015	48.2	22.1	21			20 5.9%	20.20 [5.89, 34.51]	
Daniels et al., 2009a Lee et al., 2014		22.09 19.04	119 121	26.4 23. 19.4 16.			15.10 [9.33, 20.87] 15.10 [10.50, 19.70]	
Subtotal (95% CI)	34.9	19.04	261	19.4 10.		54 100.0%	15.40 [11.92, 18.89]	•
Heterogeneity: Tau² = 0. Test for overall effect: Z			f= 2 (P	= 0.79); l²				ľ
1.2.3 Tapentadol 50 mg				ostoperat	ive hour	IS		
Chen et al., 2015	115.6	45.1	21	and the second second		20 11.6%	47.40 [13.97, 80.83]	
Daniels et al., 2009a		47.85	119	59.6 52.			33.70 [20.96, 46.44]	
Lee et al., 2014	88.4	40.24	121	53.8 4	4.6 11	4 28.8%	34.60 [23.72, 45.48]	
Stegmann et al., 2008	39.9	19.8	67	25 1		57 32.6%	14.90 [8.64, 21.16]	•
Subtotal (95% CI) Heterogeneity: Tau² = 1-	44.97; CI	hi² = 15.5	328 50, df = 3	3 (P = 0.00		2 1 100.0% 31%	29.42 [15.48, 43.36]	-
Test for overall effect: Z								
1.2.4 Tapentadol 50 mg		1000	10.000					
Chen et al., 2015	187.3	68		12.6 10:		20 17.2%		
Daniels et al., 2009a Lee et al., 2014	151.3	76.4 64.14	119	97.4 86. 94.7 76.			53.90 [33.25, 74.55] 56 60 [39 55, 74.65]	
Lee et al., 2014 Stegmann et al., 2008	151.3 49.3	64.14 24.6	121 67			14 27.2% 67 29.0%	56.60 [38.55, 74.65] 6.80 [-1.23, 14.83]	
Subtotal (95% CI)	43.3	24.0	328	42.J Z.		29.0%		
Heterogeneity: Tau² = 1) Test for overall effect: Z			.49, df =	3 (P ≤ 0.0	10001); I	* = 93%		
1.2.5 Tapentadol 75 mg	versus	placebo	at 12 p	ostoperat	ive hour	rs		
Chen et al., 2015	24.4	10.3	19	13 1	1.3 2	20 11.3%	11.40 [4.62, 18.18]	+
Daniels et al., 2009a		10.96		13.7 11.			10.30 [7.43, 13.17]	
Lee et al., 2014	15.1	9.99	117	7.8 7.	21 11		7.30 [5.06, 9.54]	
Subtotal (95% CI) Heterogeneity: Tau ² = 1.				= 0.19); l²		54 100.0%	8.94 [6.49, 11.39]	
Test for overall effect: Z	= 7.15 (P	° < 0.000	101)					
1.2.6 Tapentadol 75 mg		1.000	10.20	1.1.1				
Chen et al., 2015	54.1	20.5	19			20 14.9%		
Daniels et al., 2009a		21.28	120	26.4 23.			23.20 [17.54, 28.86]	
Lee et al., 2014 Subtotal (95% CI)	35.1	19.5	117 256	19.4 16.		4 44.8% 54 100.0%	15.70 [11.00, 20.40] 20.28 [13.95, 26.60]	
Heterogeneity: Tau ² = 1 Test for overall effect: Z			df = 2 (F	° = 0.08); I			20120 [10100, 20100]	•
1.2.7 Tapentadol 75 mg			i.	ostoperat	ive hour	rs.		
Chen et al., 2015	123.5	50	19			20 10.5%	55.30 [19.93, 90.67]	
Daniels et al., 2009a		44.19	120	59.6 52.			48.60 [36.32, 60.88]	
Lee et al., 2014		41.34	117	53.8 4	4.6 11		33.80 [22.70, 44.90]	
Subtotal (95% CI)			256			54 100.0%	42.40 [30.08, 54.73]	•
Heterogeneity: Tau² = 5: Test for overall effect: Z :				r = 0.16); l	*= 46%			
1.2.8 Tapentadol 75 mg	versus	placebo	at 72 p	ostoperat	ive hour	rs		
Chen et al., 2015		74.6		12.6 10		20 7.3%	81.50 [25.19, 137.81]	
Daniels et al., 2009a	171.3	69.97		97.4 86.	25 12	20 43.7%	73.90 [54.03, 93.77]	
Lee et al., 2014	148.5	65.29	117	94.7 76.				
Subtotal (95% CI)	2 20. 04	2-252	256	0 - 0 2011		54 100.0%	64.61 [49.01, 80.22]	-
Heterogeneity: Tau ² = 4: Test for overall effect: Z :				- 0.28); I	- 21%			
1.2.9 Tapentadol 100 m							F7 70 110 00	
Daniels et al., 2009a Stogmonn et al., 2009		35.82	118	59.6 52.		20 49.2%		
Stegmann et al., 2008 Subtotal (95% CI)	44.9	21.5	68 186	25 1		67 50.8% 87 100.0%		
Heterogeneity: Tau ² = 6	91.90° CI	hi² = 31 3		(P < 0.00			50.50 [1.40, 75.54]	
Test for overall effect: Z			- 2, ui – 1	ι _ν ι - 0.00		- 31 70		
1.2.10 Tapentadol 100	1000000						05 10 107 07 100 75	_
Daniels et al., 2009a Stogmonn et al., 2009		54.85	118	97.4 86.		20 49.3% 37 60.7%		
Stegmann et al., 2008 Subtotal (95% CI)	56	21.4	68 186	42.5 2:		67 50.7% 87 100.0%	13.50 [6.04, 20.96] 48.94 [-21.51, 119.40]	
Heterogeneity: Tau ² = 2:	533.81: 0	Chi² = 50		1 (P < 0.0				
Test for overall effect: Z				, 0.0		•		
								-100 -50 0 50 100
Foot for outprocess all the second			102 4	0.00.00	000043	IZ - 02 CO		Placebo Tapentadol
Test for subgroup differ	ences: C	ni* = 120	J.93, df=	ะ 9 (P < 0.1	UUUU1),	17 = 92.6%		

Figure 4. Meta-analysis of TOTPAR [6,7,9,10].

The global evaluation of the treatments (patient satisfaction) was carried out with five clinical trials and showed that any dose of tapentadol IR—50 mg (n = 603), 75 mg (n = 534), and 100 mg (n = 186)—was better evaluated by the patients compared to the placebo (n = 390, n = 323, and n = 187, respectively) (Figure 5) [6–10]. In addition, the NNT shows that 3.8 (95% CI = 3.1 to 4.9) patients must be treated with tapentadol IR 50 mg to obtain one analgesic success that would not have occurred with the placebo. In this sense, the NNT for tapentadol IR 75 mg and tapentadol IR 100 mg was 2.9 (95% CI = 2.5 to 3.6) and 2.2 (95% CI = 1.8 to 2.7) in comparison with the placebo, respectively. Statistical analysis of the global assessment data showed low heterogeneity, so the fixed effects model was used (Figure 5) [6–10].

	Tapent	adol	Place	bo		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.3.1 Tapentadol 50 mg	versus p	lacebo					
Chen et al., 2015	15	21	8	20	4.7%	3.75 [1.02, 13.80]	· · · · · · · · · · · · · · · · · · ·
Daniels et al., 2009a	80	119	49	120	32.2%	2.97 [1.75, 5.04]	
Daniels et al., 2009b	228	275	45	69	24.8%	2.59 [1.44, 4.65]	
Lee et al., 2014	98	121	60	114	23.7%	3.83 [2.14, 6.88]	
Stegmann et al., 2008	56	67	44	67	14.6%	2.66 [1.17, 6.04]	
Subtotal (95% CI)		603		390	100.0%	3.07 [2.29, 4.12]	•
Total events	477		206				
Heterogeneity: Chi ² = 1.		•		%			
Test for overall effect: Z	= 7.48 (P <	< 0.0001	01)				
1.3.2 Tapentadol 75 mg	versus n	lacebo					
Chen et al., 2015	14	19	8	20	6.4%	4.20 [1.08, 16.32]	
Daniels et al., 2009a	92	120	49	120	35.8%	4.76 [2.72, 8.32]	ed and the second se
Daniels et al., 2009b	245	278	45	69	26.8%	3.96 [2.14, 7.32]	
Lee et al., 2014	98	117	60	114	30.9%	4.64 [2.51, 8.57]	
Subtotal (95% CI)	00	534	00		100.0%	4.47 [3.21, 6.24]	•
Total events	449		162				-
Heterogeneity: Chi ² = 0.		P = 0.9		Х.			
Test for overall effect: Z	10 · · · · · · · · · · · · · · · · · · ·	•		-			
	,						
1.3.3 Tapentadol 100 m	ng versus	placebo	0				
Daniels et al., 2009a	105	118	49	120	69.8%	11.70 [5.92, 23.14]	
Stegmann et al., 2008	64	68	39	67	30.2%	11.49 [3.75, 35.23]	
Subtotal (95% CI)		186		187	100.0%	11.64 [6.49, 20.86]	•
Total events	169		88				
Heterogeneity: Chi ² = 0.	00, df = 1 i	(P = 0.9	8); I ² = 09	Х6			
Test for overall effect: Z	= 8.24 (P <	< 0.000	01)				
							0.02 0.1 1 10 50
225 725 22 232		2 1992-11	2002	1945) - 1949)		0.000	Placebo Tapentadol
Test for subgroup differ	ences: Ch	$i^2 = 16.1$	19, df = 2	(P = 0.	0003), I² =	= 87.6%	

Figure 5. Combined analysis of the global evaluation [6–10].

3.4. Adverse Effects

The pooled evaluation of the adverse effects of tapentadol IR was performed with seven clinical trials. In this sense, tapentadol IR (50 mg (n = 721, Figure 6) [6–10,12], 75 mg (n = 749, Figure 7) [6–9,11,12], and 100 mg (n = 302, Figure 8) [7,10,12]) produced a high number of adverse effects on the nervous system and gastrointestinal tract compared to the placebo (n = 510, Figure 6; n = 542, Figure 7; and n = 307, Figure 8). Table 2 shows the NNH and 95% CI of the adverse effects of tapentadol IR compared to the placebo. The evaluation of the adverse effects of the three doses of tapentadol IR used showed high heterogeneity (at least in one adverse effect evaluated), so it was decided to carry out the three meta-analyses using the random effects model.

Study or Subgroup	Tapentadol !	-	Placel		Woight	Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	evenus	rotal	weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
	-		1943		0.4.00	0.50 14 05 00 001	1.17
Chen et al., 2015	7	21	1	20	2.1%	9.50 [1.05, 86.26]	
_ee et al., 2014	44	121	8	114	15.0%	7.57 [3.37, 16.99]	and the second
Stegmann et al., 2008	31	67	12	67	15.8%	3.95 [1.80, 8.68]	State of the second
Daniels et al., 2009b	93	275	12	69	21.4%	2.43 [1.24, 4.75]	
(u et al., 2012	42	118	16	120	22.8%	3.59 [1.88, 6.86]	
Daniels et al., 2009a	42	119	16	120	22.9%	3.55 [1.86, 6.77]	
Subtotal (95% CI)	0.50	721	0.5	510	100.0%	3.82 [2.77, 5.26]	•
Total events Heterogeneity: Tau² = 0. Test for overall effect: Za			65 P = 0.38);	I ² = 59	6		
2.1.2 Dizziness							
Chen et al., 2015	14	21	1	20	8.9%	38.00 [4.18, 345.04]	
_ee et al., 2014	20	121	3	114	18.3%	7.33 [2.11, 25.40]	
Daniels et al., 2009a	19	119	6	120	22.9%	3.61 [1.39, 9.39]	
Daniels et al., 2009b	41	275	7	69	24.9%	1.55 [0.66, 3.63]	_
Stegmann et al., 2008	22	67	10	67	25.0%	2.79 [1.20, 6.48]	
Subtotal (95% CI)		603			100.0%	3.85 [1.81, 8.19]	•
Fotal events	116		27				
Heterogeneity: Tau² = 0. Fest for overall effect: Z	41; Chi² = 9.61			I² = 58	%		
2.1.3 Vomiting							
Chen et al., 2015	4	21	0	20	4.4%	10.54 [0.53, 209.77]	
Daniels et al., 2009b	34	275	0	69	5.0%	19.86 [1.20, 328.03]	
Stegmann et al., 20090	34 11	67	1	67	9.1%	12.96 [1.62, 103.55]	· · · · · · · · · · · · · · · · · · ·
(u et al., 2012	22	118	3	120	25.7%	8.94 [2.60, 30.76]	
Daniels et al., 2009a	22	119	3	120	25.7%	8.85 [2.57, 30.44]	
_ee et al., 2014	14	121	4	114	30.1%	3.60 [1.15, 11.28]	
Subtotal (95% CI)	14	721	4		100.0%	7.35 [3.93, 13.76]	▲
Fotal events	107	121	11	010	100.070	1100 [0100, 10110]	•
Heterogeneity: Tau² = 0. Fest for overall effect: Z			P = 0.76);	I² = 09	6		
2.1.4 Somnolence							
Chen et al., 2015	3	21	0	20	6.4%	7.76 [0.38, 160.40]	
Daniels et al., 2009a	14	119	1	120	14.0%	15.87 [2.05, 122.72]	
Daniels et al., 2009b	20	275	2	69	26.8%	2.63 [0.60, 11.52]	
Stegmann et al., 2008	19	67	5	67	52.7%	4.91 [1.71, 14.09]	
Subtotal (95% CI)		482		276	100.0%	5.04 [2.34, 10.84]	•
Total events	56		8				
Heterogeneity: Tau² = 0. Fest for overall effect: Z			P = 0.56);	² = 09	6		
2.1.5 Headache							
Chen et al., 2015	3	21	1	20	4.1%	3.17 [0.30, 33.31]	
Stegmann et al., 2008	12	67	7	67	22.8%	1.87 [0.69, 5.09]	
Daniels et al., 2009a	14	119	8	120	27.6%	1.87 [0.75, 4.63]	+
	56	275	11	69	45.5%	1.35 [0.66, 2.74]	 _
Janiels et al 7009n	50	482			100.0%	1.65 [1.02, 2.65]	•
						[-
Subtotal (95% CI)	85		27				
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0.			27 P = 0.86);	I ^z = 09	6		
Subtotal (95% Cl) Fotal events Heterogeneity: Tau² = 0. Fest for overall effect: Z	00; Chi² = 0.74			l² = 09	6		
Daniels et al., 2009b Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0. Fest for overall effect: Z 2.1.6 Constipation Etogmann et al. 2009	00; Chi² = 0.74 = 2.04 (P = 0.0	4)	° = 0.86);			4.10 10 40 - 00 500	
Subtotal (95% CI) Fotal events Heterogeneity: Tau² = 0. Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008	00; Chi² = 0.74 = 2.04 (P = 0.0 4	4) 67	o = 0.86); 1	67	18.0%	4.19 [0.46, 38.52]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0. Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014	00; Chi² = 0.74 = 2.04 (P = 0.0 4 7	4) 67 121	P = 0.86); 1 1	67 114	18.0% 19.9%	6.94 [0.84, 57.31]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0 Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014 Ku et al., 2012	00; Chi ^z = 0.74 = 2.04 (P = 0.0 4 7 8	4) 67 121 118	P = 0.86); 1 1 1	67 114 120	18.0% 19.9% 20.2%	6.94 [0.84, 57.31] 8.65 [1.07, 70.32]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0 Fest for overall effect: Z: 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014 Ku et al., 2012 Daniels et al., 2009a	00; Chi ^z = 0.74 = 2.04 (P = 0.0 4 7 8 8	4) 67 121 118 119	P = 0.86); 1 1 1 1	67 114 120 120	18.0% 19.9% 20.2% 20.2%	6.94 [0.84, 57.31] 8.65 [1.07, 70.32] 8.58 [1.06, 69.68]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0. Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014 (u et al., 2012 Daniels et al., 2009a Daniels et al., 2009b	00; Chi ^z = 0.74 = 2.04 (P = 0.0 4 7 8	4) 67 121 118 119 275	P = 0.86); 1 1 1	67 114 120 120 69	18.0% 19.9% 20.2% 20.2% 21.7%	6.94 [0.84, 57.31] 8.65 [1.07, 70.32] 8.58 [1.06, 69.68] 5.91 [0.78, 44.66]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0. Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014 Cu et al., 2012 Daniels et al., 2009a Daniels et al., 2009b Subtotal (95% CI)	00; Chi ^z = 0.74 = 2.04 (P = 0.0 4 7 8 8 22	4) 67 121 118 119	^D = 0.86); 1 1 1 1 1	67 114 120 120 69	18.0% 19.9% 20.2% 20.2%	6.94 [0.84, 57.31] 8.65 [1.07, 70.32] 8.58 [1.06, 69.68]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0. Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014 Cu et al., 2014 Daniels et al., 2009a Daniels et al., 2009b Subtotal (95% CI) Fotal events	00; Chi ⁼ = 0.74 = 2.04 (P = 0.0 4 7 8 8 8 22 49	4) 67 121 118 119 275 700	P = 0.86); 1 1 1 1 1 5	67 114 120 120 69 490	18.0% 19.9% 20.2% 20.2% 21.7% 100.0%	6.94 [0.84, 57.31] 8.65 [1.07, 70.32] 8.58 [1.06, 69.68] 5.91 [0.78, 44.66]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0. Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014 Caniels et al., 2009a Daniels et al., 2009a Daniels et al., 2009b Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0.	00; Chi ² = 0.74 = 2.04 (P = 0.04 4 7 8 8 8 22 49 00; Chi ² = 0.30	4) 67 121 118 119 275 700 I, df = 4 (1	P = 0.86); 1 1 1 1 1 5	67 114 120 120 69 490	18.0% 19.9% 20.2% 20.2% 21.7% 100.0%	6.94 [0.84, 57.31] 8.65 [1.07, 70.32] 8.58 [1.06, 69.68] 5.91 [0.78, 44.66]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0 Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014 Ku et al., 2012	00; Chi ² = 0.74 = 2.04 (P = 0.04 4 7 8 8 8 22 49 00; Chi ² = 0.30	4) 67 121 118 119 275 700 I, df = 4 (1	P = 0.86); 1 1 1 1 1 5	67 114 120 120 69 490	18.0% 19.9% 20.2% 20.2% 21.7% 100.0%	6.94 [0.84, 57.31] 8.65 [1.07, 70.32] 8.58 [1.06, 69.68] 5.91 [0.78, 44.66]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0. Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014 Caniels et al., 2009a Daniels et al., 2009a Daniels et al., 2009b Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0.	00; Chi ² = 0.74 = 2.04 (P = 0.04 4 7 8 8 8 22 49 00; Chi ² = 0.30	4) 67 121 118 119 275 700 I, df = 4 (1	P = 0.86); 1 1 1 1 1 5	67 114 120 120 69 490	18.0% 19.9% 20.2% 20.2% 21.7% 100.0%	6.94 [0.84, 57.31] 8.65 [1.07, 70.32] 8.58 [1.06, 69.68] 5.91 [0.78, 44.66]	
Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0. Fest for overall effect: Z 2.1.6 Constipation Stegmann et al., 2008 Lee et al., 2014 Caniels et al., 2009a Daniels et al., 2009a Daniels et al., 2009b Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0.	00; Chi ² = 0.74 = 2.04 (P = 0.04 4 7 8 8 8 22 49 00; Chi ² = 0.30	4) 67 121 118 119 275 700 I, df = 4 (1	P = 0.86); 1 1 1 1 1 5	67 114 120 120 69 490	18.0% 19.9% 20.2% 20.2% 21.7% 100.0%	6.94 [0.84, 57.31] 8.65 [1.07, 70.32] 8.58 [1.06, 69.68] 5.91 [0.78, 44.66]	0.002 0.1 1 10 51 Tapentadol 50 mg Placebo

Figure 6. Meta-analysis of the adverse effects of 50 mg of tapentadol [6–10,12].

Total	Events	lotal	weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
4.0		20	2.00	40.00 14 50 405 051	
19	1	20	2.8%	13.82 [1.52, 125.65]	1.000
120	16	120	20.3%	3.90 [2.05, 7.42]	
278	12	69	19.6%	4.00 [2.05, 7.77]	Sec. Sec. Sec. Sec. Sec. Sec. Sec. Sec.
117 96	8	114	15.4%	10.60 [4.74, 23.73]	
	24 16	99	21.6% 20.3%	2.88 [1.56, 5.29]	
119 749	10	120	100.0%	3.81 [2.00, 7.27] 4.41 [3.01, 6.48]	
145	77	JTL	100.070	4.41 [5.01, 0.40]	•
df = 5.0	P = 0.16)	· Z = 3	696		
)001)	1 - 0.10	, i = 0	0.0		
19	1	20	9.6%	101.33 [9.58, 1071.99]	
120	6	120	22.4%	5.26 [2.08, 13.30]	
278	7	69	23.7%	2.92 [1.28, 6.69]	
117	3	114	19.0%	11.64 [3.43, 39.54]	
96	17	99	25.4%	2.09 [1.06, 4.12]	-
630		422	100.0%	5.59 [2.31, 13.53]	•
	34				
4, df = 4)01)	(P = 0.00	05); I² =	= 73%		
19	0	20	3.6%	45.32 [2.40, 856.74]	
120	3	120	20.6%	10.26 [3.01, 35.03]	
278	0	69	4.0%	53.46 [3.27, 873.96]	
117	4	114	26.2%	7.86 [2.65, 23.34]	
96	4	99	25.1%	6.65 [2.19, 20.20]	
119	3	120	20.5%	9.85 [2.88, 33.72]	
749		542	100.0%	9.58 [5.49, 16.73]	•
	14				
, df = 5 (F)001)	P = 0.63)	; ² = 0	%		
19	0	20	6.7%	5.86 [0.26, 130.36]	
120	1	120	15.5%	18.31 [2.39, 140.42]	
278	2	69	30.7%	5.14 [1.21, 21.89]	
96	4	99	47.1%	3.39 [1.05, 10.92]	
513		308	100.0%	5.19 [2.33, 11.59]	•
	7				
, df = 3 (f)01)	P = 0.56)	; I² = 0	%		
19	1	20	2.9%	2.24 [0.19, 26.91]	
120	8	120	21.6%	1.70 [0.68, 4.27]	
278	11	69	36.1%	1.21 [0.60, 2.47]	
96	24	99	39.4%	0.77 [0.39, 1.52]	_ _
513	27		100.0%	1.11 [0.72, 1.70]	•
	44				
, df = 3 (F 3)	P = 0.51)	; I² = 0	%		
53					
120	1	120	8.3%	1.00 [0.06, 16.17]	
278	1	69	15.4%	3.88 [0.50, 29.88]	
117	1	114	14.6%	8.29 [1.02, 67.42]	
96	5	99	53.4%	2.43 [0.81, 7.29]	
119	1	120	8.3%	1.01 [0.06, 16.31]	
730			100.0%	2.70 [1.21, 6.02]	•
	9				•
df = 4 f		$ \mathbf{r} = 0$	%		
, ui – 4 (i 2)	0.00)	0	~~		
· ·					
					0.001 0.1 1 10 100 Tapentadol 75 mg Placebo
2))))

Figure 7. Combined analysis of the adverse effects of 75 mg of tapentadol [6–9,11,12].

Study or Subaroup	Tapentadol 10	-	Place		Woight	Odds Ratio	Odds Ratio
Study or Subgroup 2.3.1 Nausea	Events	TUId	Events	TUtal	weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Daniels et al., 2009a	58	118	16	120	38.0%	6.28 [3.32, 11.89]	-
Stegmann et al., 2008a	45	68	10	67	24.1%	8.97 [4.02, 19.99]	
(u et al., 2012	56	116	16	120	37.8%	6.07 [3.20, 11.51]	
Subtotal (95% CI)	50	302	10		100.0%	6.76 [4.56, 10.02]	•
Total events	159		44				
Heterogeneity: Tau ² = 0.	00; Chi ² = 0.64,		0.00	²= 0%			
Test for overall effect: Z	= 9.51 (P < 0.00	001)					
2.3.2 Dizziness							
Daniels et al., 2009a	37	118	6	120	45.9%	8.68 [3.50, 21.53]	
Stegmann et al., 2008 Subtotal (95% Cl)	44	68 186	10	67 187	54.1% 100.0%	10.45 [4.53, 24.11] 9.60 [5.19, 17.75]	↓
Total events	81		16				
Heterogeneity: Tau² = 0 Test for overall effect: Z			= 0.77); I	²= 0%			
2.3.3 Vomiting							
Daniels et al., 2009a	38	118	3	120	42.6%	18.52 [5.53, 62.08]	
Stegmann et al., 2008	24	68	1	67	15.0%	36.00 [4.70, 275.87]	
Ku et al., 2012 Subtotal (95% Cl)	36	116 302	3	120 307	42.4% 100.0%	17.55 [5.22, 58.95] 20.00 [9.09, 44.04]	•
Total events	98		7				
Heterogeneity: Tau² = 0 Test for overall effect: Z			= 0.83); l	²= 0%			
2.3.4 Somnolence							
Daniels et al., 2009a	25	118	1	120	34.3%	31.99 [4.26, 240.45]	
Stegmann et al., 2008 Subtotal (95% CI)	25	68 186	5	67 187	65.7% 100.0%	7.21 [2.56, 20.31] 12.01 [2.78, 51.93]	-
Total events	50		6				
Heterogeneity: Tau² = 0 Test for overall effect: Z	57; Chi² = 1.85,		= 0.17); I	²= 46%	b		
2.3.5 Headache							
Daniels et al., 2009a	14	118	8	120	53.3%	1.88 [0.76, 4.68]	+
Stegmann et al., 2008	15	68	7	67	46.7%	2.43 [0.92, 6.40]	
Subtotal (95% CI)		186			100.0%	2.12 [1.09, 4.12]	◆
Total events	29		15				
Heterogeneity: Tau² = 0. Test for overall effect: Z			= 0.71); l	²= 0%			
2.3.6 Constinution					100000000	10 47 14 70 405 051	
2.3.6 Constipation	12	110	1	120	31 694		
Daniels et al., 2009a	12	118	1	120	34.6% 30.9%	13.47 [1.72, 105.35]	
Daniels et al., 2009a Stegmann et al., 2008	5	68	1	67	30.9%	5.24 [0.60, 46.09]	
Daniels et al., 2009a Stegmann et al., 2008 Ku et al., 2012				67 120		5.24 [0.60, 46.09] 13.73 [1.76, 107.40]	
Daniels et al., 2009a Stegmann et al., 2008 Ku et al., 2012 Subtotal (95% CI)	5 12	68 116	1	67 120	30.9% 34.5%	5.24 [0.60, 46.09]	
Daniels et al., 2009a Stegmann et al., 2008 Ku et al., 2012	5 12 29 00; Chi≇ = 0.52,	68 116 302 df = 2 (P	1 1 3	67 120 307	30.9% 34.5%	5.24 [0.60, 46.09] 13.73 [1.76, 107.40]	
Daniels et al., 2009a Stegmann et al., 2008 Ku et al., 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = 0	5 12 29 00; Chi≇ = 0.52,	68 116 302 df = 2 (P	1 1 3	67 120 307	30.9% 34.5%	5.24 [0.60, 46.09] 13.73 [1.76, 107.40]	
Daniels et al., 2009a Stegmann et al., 2008 Ku et al., 2012 Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = 0	5 12 29 00; Chi≇ = 0.52,	68 116 302 df = 2 (P	1 1 3	67 120 307	30.9% 34.5%	5.24 [0.60, 46.09] 13.73 [1.76, 107.40]	0.002 0.1 1 10 50 Tapentadol 100 mg Placebo

Figure 8. Pooled data analysis of the adverse effects of 100 mg of tapentadol [7,10,12].

Table 2. The NNH and 95% IC for tapentadol when compared to the placebo.

	Tapent	adol 50 mg	Tap	entadol 75 mg	Tapentadol 100 mg		
_	NNH	95% CI	NNH	95% CI	NNH	95% CI	
Nausea	4.3	3.5 to 5.4	3.4	2.9 to 4.1	2.5	2 to 3.2	
Dizziness	8.1	6.1 to 12.1	5.4	4.4 to 7	2.9	2.3 to 3.7	
Vomiting	8.3	6.6 to 11.2	4.4	3.8 to 5.3	3.2	2.6 to 4.1	
Somnolence	11.5	8.2 to 19.1	9.3	7.1 to 13.5	4.2	3.3 to 5.9	
Headache	12.7	7.9 to 33.7	40.3	13.2 to infinity	13.2	7.1 to 94.1	
Constipation	16.8	12.1 to 27.5	26.8	16.6 to 69.2	12.4	8 to 27.2	

4. Discussion

To our knowledge, this is the first systematic review to use data from other studies to perform a statistical analysis to determine the dose with the best analgesic efficacy and tolerability of tapentadol IR in a kind of specific surgery, a bunionectomy. The metaanalyses performed showed that the analgesic efficacy of tapentadol IR is dose-dependent; that is, patients reported better pain relief with higher doses. In the same way, the metaanalyses demonstrated that the adverse effects also depend on the dose of tapentadol IR; that is, the higher the dose used, the greater the number of patients reported adverse effects.

According to the Cochrane bias assessment tool, the risk of bias in the studies included in this study was low to moderate. Items from the Cochrane bias assessment tool least likely to be biased were incomplete data reporting and selective reporting, while studies most likely to be biased were those that made reference to blinding. In all cases, the specifications of who was blinded were not included in the articles, and only the term double-blind was included, so these terms were classified as unclear risk of bias (Figure 2).

Qualitative analysis showed that tapentadol IR produces better postoperative pain relief compared to a placebo after bunion surgery. Through the characteristics of each study included in this systematic review and meta-analysis, a standardized surgical procedure can be observed, minimizing possible biases due to differences in the execution of the surgery (Table 1).

The analgesic efficacy of tapentadol IR (n = 1323) compared to the placebo (n = 390) was evaluated in a total of 1713 patients through a global evaluation of the treatments. All three doses of tapentadol IR showed better results compared to the placebo after the bunionectomy. Based on the NNT, 100 mg of tapentadol could be considered the most effective dose for postoperative pain control, as it had the lowest NNT = 2.2 (95% CI = 1.8 to 2.7) compared to tapentadol IR 50 mg NNT = 3.8 (95% CI = 3.1 to 4.9) and tapentadol IR 75 mg NNT = 2.9 (95% CI = 2.5 to 3.6). However, the statistical analysis of tapentadol IR 100 mg versus the placebo had a smaller sample size (n = 373) compared to tapentadol IR 75 mg (n = 993) and tapentadol IR 75 mg (n = 857). It is important to note that the global evaluation of the treatments was the most powerful analgesic indicator to determine the analgesic efficacy of the three doses of tapentadol IR because pooled data analysis and NNT calculations were possible. Likewise, it is important to emphasize that the heterogeneity of this meta-analysis was null in the three comparisons that were made, which allowed the use of the fixed effects method and greater power in the data analysis.

A systematic review and meta-analysis to assess the analgesic efficacy of tapentadol in different types of surgery have been previously reported. Xiao et al., 2017 [22], performed a meta-analysis to assess the analgesic efficacy and safety of tapentadol in a bunionectomy, a hysterectomy, end-stage joint disease, and joint replacement surgery. This study compared the analgesic efficacy of tapentadol versus a placebo using the SPID clinical indicator at 48 h post-surgery, demonstrating that doses of 50 mg, 75 mg, and 100 mg of this drug are better than a placebo for controlling postoperative pain by the evaluation of pooled data obtained in studies with these different types of surgery. Likewise, this study compared the analgesic efficacy of tapentadol at doses of 50 mg, 75 mg, and 100 mg versus oxycodone at doses of 10 mg and 15 mg. In all cases where a cluster analysis is shown to compare these two analgesics, *p*-values with no statistical difference were obtained. Therefore, we could conclude that these drugs might have similar analgesic efficacy, indicating a problem, with the different types of surgery included in this statistical analysis. Our study only included studies that reported the analgesic efficacy of tapentadol IR compared to a placebo in a bunionectomy using three indicators of analgesic efficacy: SPID, TOTPAR, and global assessment of analgesics.

A total of 2381 participants were included in the evaluation of the adverse effects of tapentadol IR (n = 1772) in comparison to the placebo (n = 609) in a bunionectomy. Like the analgesic effect of tapentadol IR, the adverse effects have a direct relationship depending on the dose, and tapentadol IR 100 mg was the dose that presented the greatest number of adverse effects. According to the NNH, it is necessary to administer tapentadol IR

100 mg to 2.5 patients for 1 patient to experience nausea, while for this to happen with tapentadol IR 75 mg and tapentadol IR 50 mg, it is necessary that 3.4 and 4.3 patients receive tapentadol, respectively.

Currently, international organizations support the use of multimodal analgesia to treat postoperative pain [23]. The use of a combination of analgesics (NSAIDs, glucocorticoids, and opioids) could have many advantages, such as the induction of analgesia by different mechanisms of action, improved rapid recovery after surgery, less general toxicity, and adverse effects because the combination of drugs allows reducing the doses, particularly how much synergistic analgesic effects can be obtained using a combination of two or more drugs [24–30]. It is important to mention that evidence can also be found in clinical trials on the use of other opioid analgesics alone, or in combination with other types of drugs, to treat postoperative pain after a bunionectomy, such as tramadol [31,32], oxycodone [7,33–35], and morphine [33,36,37].

Several systematic reviews and meta-analyses have been performed to assess both the analgesic efficacy and adverse effects of tapentadol in different areas of medicine. Etropolski et al., 2014, conducted a systematic review and meta-analysis to assess the adverse effects of a placebo, oxycodone, and tapentadol for the treatment of pain in osteoarthritis and lower back pain. Quantitative results show that the placebo was safer than both drugs, while tapentadol had fewer adverse effects on the gastrointestinal tract and central nervous system compared with oxycodone [38]. Santos et al., 2015, conducted a systematic review and meta-analysis to assess the efficacy and adverse effects of a placebo, oxycodone, and tapentadol in musculoskeletal pain. The results of this study showed a lower incidence of adverse effects of the placebo compared to both drugs, while tapentadol showed a better safety profile than oxycodone [39]. Wiffen et al., 2015, reported that tapentadol, morphine, and oxycodone had similar safety profiles or adverse effects in studies conducted for cancer pain relief [40]. Xiao et al., 2016, demonstrated that tapentadol IR 50 mg and 75 mg produced fewer adverse effects compared to oxycodone when these drugs were administered to patients undergoing different surgical procedures [22]. Meng et al., 2017, evaluated the prevalence of adverse effects of different opioid analgesics and reported that tapentadol had the lowest number of adverse effects [41]. In our systematic review and meta-analysis, the adverse effects of tapentadol on the central nervous system and the gastrointestinal tract were included in our pooled evaluation. All comparisons showed that tapentadol has a higher number of adverse effects compared to the placebo. However, considering a risk-benefit ratio, it could be considered that the analgesic efficacy of tapentadol is greater than the risk of adverse effects. It is important to note that serious adverse effects were not reported in any of the studies included in this systematic review and meta-analysis.

This is the first systematic review that analyzes pooled data to determine the analgesic efficacy and adverse effects of IR tapentadol after a bunionectomy, achieving the largest sample size reported to date in this surgical area. In this sense, it is important to mention that the meta-analyses carried out in this study present highly variable heterogeneity (low, moderate, and high heterogeneity). On the other hand, this study allows us to know the efficacy of tapentadol for the control of postoperative pain in patients with a bunionectomy, which was achieved thanks to the collection of available information to perform statistical calculations (NNT and NND) that can be applied by the physician in the care of the patients. In both cases—the evaluation of efficacy and adverse effects—it was possible to calculate the NNT and NNH, which adds clinical importance to the use of tapentadol in this surgical area and that if there are other similar studies that evaluate other analgesics, could help decide which medication might be the best treatment option. Furthermore, it is important to note that only studies with low or unclear risk of bias according to the Cochrane tool were included in this systematic review and meta-analysis [42-44]. These represent the advantages of our study. On the other hand, the main drawback of this study stems from its retrospective design and publication bias [42–44].

Based on the global evaluation of patient satisfaction, it is concluded that the 100 mg dose of tapentadol IR is the one that obtained the best satisfaction score. This could be interpreted as patients experiencing less pain during the postoperative evaluation period and fewer adverse effects, which would make this dose of tapentadol IR the most clinically effective for treating postoperative pain in patients undergoing bunion surgery.

Author Contributions: Conceptualization, M.A.I.-E. and O.H.A.-M.; investigation, A.H.-G., L.F.d.I.T., E.G.-S., J.M.G.-F., A.J.A.-C., D.L.F.-G. and V.G.-S.; writing—original draft preparation, M.A.I.-E., A.J.A.-C. and V.G.-S.; writing—review and editing, A.H.-G., D.L.F.-G. and J.M.G.-F.; supervision, M.A.I.-E., L.F.-d.I.T., E.G.-S. and V.G.-S. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the Programa de Apoyo a la Mejora de las Condiciones de Producción de los Miembros del SIN y SNCA-PROSNI 2023 of the Universidad de Guadalajara.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data supporting the findings of this study are available in each included article, and pooled data are contained in this article.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Wang, H.; Gargano, C.; Lukac, S.; Jackson, A.; Beals, C.; Smiley, P.; Drexel, M.; Ruddy, M.; Herman, G.; Johnson-Levonas, A.O.; et al. An enhanced bunionectomy model as a potential tool for early decision-making in the development of new analgesics. *Adv. Ther.* 2010, 27, 963–980. [CrossRef] [PubMed]
- 2. Willens, J.S.; Bucior, I.; Bujanover, S.; Mehta, N. Assessment of rescue opioid use in patients with post-bunionectomy pain treated with diclofenac potassium liquid-filled capsules. *J. Pain Res.* **2015**, *8*, 53–62. [CrossRef]
- 3. Gottlieb, I.J.; Tunick, D.R.; Mack, R.J.; McCallum, S.W.; Howard, C.P.; Freyer, A.; Du, W. Evaluation of the safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate-to-severe pain after bunionectomy. *J. Pain Res.* **2018**, *11*, 383–393. [CrossRef]
- 4. Ravanbod, H.R. Analgesic efficacy of local versus proximal nerve blocks after hallux valgus surgery: A systematic review. J. Foot Ankle Res. 2022, 15, 78. [CrossRef]
- Isiordia-Espinoza, M.A.; Sánchez-Prieto, M.; Tobías-Azúa, F.; Reyes-García, J.G.; Granados-Soto, V. Pre-emptive analgesia with the combination of tramadol plus meloxicam for third molar surgery: A pilot study. *Br. J. Oral Maxillofac. Surg.* 2012, 50, 673–677. [CrossRef]
- 6. Chen, Y.J.; Chiang, C.C.; Huang, P.J.; Huang, J.; Karcher, K.; Li, H. Tapentadol immediate-release for acute postbunionectomy pain: A phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan. *Curr. Med. Res. Opin.* **2015**, *31*, 2001–2009. [CrossRef]
- Daniels, S.E.; Upmalis, D.; Okamoto, A.; Lange, C.; Häeussler, J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. *Curr. Med. Res. Opin.* 2009, 25, 765–776. [CrossRef]
- Daniels, S.; Casson, E.; Stegmann, J.U.; Oh, C.; Okamoto, A.; Rauschkolb, C.; Upmalis, D. A randomized, double-blind, placebocontrolled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. *Curr. Med. Res. Opin.* 2009, 25, 1551–1561. [CrossRef]
- Lee, Y.K.; Ko, J.S.; Rhim, H.Y.; Lee, E.J.; Karcher, K.; Li, H.; Shapiro, D.; Lee, H.S. Acute postoperative pain relief with immediaterelease tapentadol: Randomized, double-blind, placebo-controlled study conducted in South Korea. *Curr. Med. Res. Opin.* 2014, 30, 2561–2570. [CrossRef]
- Stegmann, J.U.; Weber, H.; Steup, A.; Okamoto, A.; Upmalis, D.; Daniels, S. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. *Curr. Med. Res. Opin.* 2008, 24, 3185–3196. [CrossRef]
- Viscusi, E.R.; Allard, R.; Sohns, M.; Eerdekens, M. Tapentadol immediate release for moderate to severe acute post-surgery pain. J. Opioid Manag. 2019, 15, 51–67. [CrossRef]
- Xu, X.S.; Etropolski, M.; Upmalis, D.; Okamoto, A.; Lin, R.; Nandy, P. Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR. *Pharm. Res.* 2012, 29, 2555–2564. [CrossRef]
- 13. Leonardo, R. PICO: Model for clinical questions. Evid. Based Med. Pract. 2008, 3, 2.
- 14. Higgins, P.P.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011], The Cochrane Collaboration, Oxford. 2011. Available online: https://www.cochrane-handbook.org/ (accessed on 25 April 2023).

- 15. Jones, A.; Steel, D. Evaluating the quality of medical evidence in real-world contexts. *J. Eval. Clin. Pract.* **2018**, *24*, 950–956. [CrossRef]
- 16. Atkins, D.; Eccles, M.; Flottorp, S.; Guyatt, G.H.; Henry, D.; Hill, S.; Liberati, A.; O'Connell, D.; Oxman, A.D.; Phillips, B.; et al. Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group. *BMC Health Serv. Res.* **2004**, *4*, 38. [CrossRef]
- 17. Guyatt, G.H.; Oxman, A.D.; Vist, G.E.; Kunz, R.; Falck-Ytter, Y.; Alonso-Coello, P.; Schünemann, H.J.; GRADE Working Group. An emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* **2008**, *336*, 924–926. [CrossRef]
- 18. Huynh, T.M.; Marret, E.; Bonnet, F. Combination of dexamethasone and local anaesthetic solution in peripheral nerve blocks: A meta-analysis of randomised controlled trials. *Eur. J. Anaesthesiol.* **2015**, *32*, 751–758. [CrossRef]
- 19. Whitley, E.; Ball, J. Statistics review 3: Hypothesis testing and P values. Crit. Care 2002, 6, 222–225. [CrossRef]
- 20. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. *BMJ* 2003, 327, 557–560. [CrossRef]
- 21. Risk Reduction Calculator. Available online: http://araw.mede.uic.edu/cgi-bin/nntcalc.pl (accessed on 17 May 2023).
- 22. Xiao, J.P.; Li, A.L.; Feng, B.M.; Ye, Y.; Wang, G.J. Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: A systematic review and meta-analysis. *Pain Med.* **2017**, *18*, 14–24. [CrossRef]
- 23. Rico-Plantón, J.M. Systematic review for analgesics treatments for the postoperative in foot and ankle surgeries. *Rev. Española De Podol.* 2016, *27*, 18–26.
- Beverly, A.; Kaye, A.D.; Ljungqvist, O.; Urman, R.D. Essential elements of multimodal analgesia in enhanced recovery after surgery (ERAS) guidelines. *Anesthesiol. Clin.* 2017, 35, e115–e143. [CrossRef]
- Gelman, D.; Gelmanas, A.; Urbanaitė, D.; Tamošiūnas, R.; Sadauskas, S.; Bilskienė, D.; Naudžiūnas, A.; Širvinskas, E.; Benetis, R.; Macas, A. Role of multimodal analgesia in the evolving enhanced recovery after surgery pathways. *Medicina* 2018, 54, 20. [CrossRef]
- 26. Gabriel, R.A.; Swisher, M.W.; Sztain, J.F.; Furnish, T.J.; Ilfeld, B.M.; Said, E.T. State of the art opioid-sparing strategies for post-operative pain in adult surgical patients. *Expert Opin. Pharmacother.* **2019**, *20*, 949–961. [CrossRef]
- 27. Buvanendran, A.; Kroin, J.S. Multimodal analgesia for controlling acute postoperative pain. *Curr. Opin. Anaesthesiol.* **2009**, *22*, 588–593. [CrossRef]
- 28. Elvir-Lazo, O.L.; White, P.F. Postoperative pain management after ambulatory surgery: Role of multimodal analgesia. *Anesthesiol. Clin.* **2010**, *28*, 217–224. [CrossRef]
- 29. Koh, W.S.; Leslie, K. Postoperative analgesia for complex spinal surgery. Curr. Opin. Anaesthesiol. 2022, 35, 543–548. [CrossRef]
- 30. Polomano, R.C.; Fillman, M.; Giordano, N.A.; Vallerand, A.H.; Nicely, K.L.; Jungquist, C.R. Multimodal analgesia for acute postoperative and trauma-related pain. *Am. J. Nurs.* **2017**, *117* (Suppl. 1), S12–S26. [CrossRef]
- Singla, N.K.; Pollak, R.; Gottlieb, I.; Leiman, D.; Minkowitz, H.; Zimmerman, J.; Harnett, M.; Ryan, M.; Lu, L.; Reines, S. Efficacy and safety of intravenously administered tramadol in patients with moderate to severe pain following bunionectomy: A randomized, double-blind, placebo-controlled, dose-finding study. *Pain Ther.* 2020, *9*, 545–562. [CrossRef]
- 32. Viscusi, E.R.; de Leon-Casasola, O.; Cebrecos, J.; Jacobs, A.; Morte, A.; Ortiz, E.; Sust, M.; Vaqué, A.; Gottlieb, I.; Daniels, S.; et al. Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: A phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial. *Pain Pract.* **2023**, *23*, 8–22. [CrossRef]
- Richards, P.; Riff, D.; Kelen, R.; Stern, W. A phase 3, randomized, double-blind comparison of analgesic efficacy and tolerability of Q8003 vs oxycodone or morphine for moderate-to-severe postoperative pain following bunionectomy surgery. *Pain Med.* 2013, 14, 1230–1238. [CrossRef]
- Singla, N.; Barrett, T.; Sisk, L.; Kostenbader, K.; Young, J. Assessment of the safety and efficacy of extended-release oxycodone/acetaminophen, for 14 days postsurgery. *Curr. Med. Res. Opin.* 2014, 30, 2571–2578. [CrossRef]
- Daniels, S.E.; Spivey, R.J.; Singla, S.; Golf, M.; Clark, F.J. Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery. *Curr. Med. Res. Opin.* 2011, 27, 593–603. [CrossRef]
- Thipphawong, J.B.; Babul, N.; Morishige, R.J.; Findlay, H.K.; Reber, K.R.; Millward, G.J.; Otulana, B.A. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. *Anesthesiology* 2003, 99, 693–700, discussion 6A. [CrossRef]
- 37. Webster, L.; Richards, P.; Stern, W.; Kelen, R.; MoxDuo Study Group. A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain. *J. Opioid Manag.* **2010**, *6*, 329–340. [CrossRef]
- Etropolski, M.; Kuperwasser, B.; Flügel, M.; Häufel, T.; Lange, B.; Rauschkolb, C.; Laschewski, F. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: Pooled analysis of randomized controlled trials. *Adv. Ther.* 2014, *31*, 604–620. [CrossRef]
- 39. Santos, J.; Alarcão, J.; Fareleira, F.; Vaz-Carneiro, A.; Costa, J. Tapentadol for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev* 2015, 2015, CD009923. [CrossRef]
- 40. Wiffen, P.J.; Derry, S.; Naessens, K.; Bell, R.F. Oral tapentadol for cancer pain. *Cochrane Database Syst Rev* 2015, 2015, CD011460. [CrossRef]
- Meng, Z.; Yu, J.; Acuff, M.; Luo, C.; Wang, S.; Yu, L.; Huang, R. Tolerability of opioid analgesia for chronic pain: A network meta-analysis. *Sci. Rep.* 2017, 17, 1995. [CrossRef]

- 42. Panic, N.; Leoncini, E.; de Belvis, G.; Ricciardi, W.; Boccia, S. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. *PLoS ONE* **2013**, *8*, e83138. [CrossRef]
- 43. Argimon-Pallás, J.M.; Jiménez-Villa, J. Métodos de Investigación Clínica y Epidemiológica, 5th ed.; Elsevier: Barcelona, Spain, 2019.
- 44. Dawson, B.; Trapp, R.G. Bioestadística Médica, 4th ed.; Editorial El Manual Moderno: Mexico City, Mexico, 2005.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.